May 31, 2012 by Brian Orelli, PhDNo Good News for Waiting Chelsea InvestorsChelsea's rheumatoid arthritis drug fails.
May 31, 2012 by Brian Orelli, PhDLook Who's Itching for a FightGlaxo steps up the heat in its hostile takeover of Human Genome Sciences.
May 31, 2012 by Brian Orelli, PhDThe Investor's Guide to the New PDUFACongress gets it done ahead of time.
May 30, 2012 by Brian Orelli, PhDThe Drug Works, but Is It Worth Proceeding?Alnylam faces a tough decision.
May 30, 2012 by Brian Orelli, PhDThis Biotech Will Have Revenue in 6 MonthsExelixis submits its cancer drug for FDA review.
May 30, 2012 by Brian Orelli, PhDThe Tale of 2 PatentsAmarin's investors are more worried about other companies' patents.
May 29, 2012 by Brian Orelli, PhDAbout That Stellar Data ...Vertex's data isn't as good as it first appears.
May 29, 2012 by Brian Orelli, PhDMore Than a One-Hit WonderRenenron's phase 2 cholesterol drug looks good.
May 26, 2012 by Brian Orelli, PhDHave J&J's Approval Hopes Vanished?Johnson & Johnson might have trouble sidestepping the competition.
May 25, 2012 by Brian Orelli, PhDThe Meaningless Drug Approval That Could Cost the Industry BillionsBeing able to use surrogate endpoints is important for drug developers.
May 24, 2012 by Brian Orelli, PhDShorter Timeframe, More RiskyChelsea gets updated information from the FDA.
May 23, 2012 by Brian Orelli, PhDAre 3 Failed Phase 3 Trials Enough?The NExUS between ESCAPE and MISSION is failure.
May 22, 2012 by Brian Orelli, PhDSequenom's Brief, Wondrous Agreement Sequenom and Coventry drop their agreement.
May 22, 2012 by Brian Orelli, PhDHow to Play an Arena DelayThis options strategy could be profitable if the FDA delays its decision.
May 22, 2012 by Brian Orelli, PhDToo Little, Too Late for Achillion?Achillion produces solid hepatitis C data, but competitors are out in front.
